GlaxoSmithKline plc 8.4% Potential Upside Indicated by UBS

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) has had its stock rating noted as ‘Downgrades’ with the recommendation being set at ‘NEUTRAL’ today by analysts at UBS. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. UBS have set a target price of 1650 GBX on its stock. This would imply the analyst believes there is now a potential upside of 8.4% from the opening price of 1522 GBX. Over the last 30 and 90 trading days the company share price has increased 46.8 points and decreased 60 points respectively. The 52 week high for the share price is currently at 1648.8 GBX while the year low share price is currently 1179.39 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,522.61 GBX and a 200 day moving average of 1,544.31. There are currently 4,964,922,506 shares in issue with the average daily volume traded being 8,475,717. Market capitalisation for LON:GSK is £75,963,314,341 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search